New Platform Detects MicroRNA Directly in Serum and Plasma
|
By LabMedica International staff writers Posted on 20 Oct 2015 |
|
Biotech and other life science researchers will benefit from the introduction of a novel microRNA (miRNA) detection platform.
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
The biotechnology company SomaGenics (Santa Cruz, CA, USA) has announced the launch of its novel miR-ID platform and assays for detecting miRNA using a circularization-based RT-qPCR method.
The miR-ID platform is highly sensitive, uses single-dye detection, and can discriminate miRNA isoforms with single nucleotide differences at any position along the molecule. The technology works well with all sample sources, including total RNA, cell lysates, and tissue lysates.
"The miR-ID miRNA detection platform is highly sensitive and provides much better sequence discrimination than leading competitors," said Brian Johnston, CEO of SomaGenics. "By using unmodified DNA primers, single-dye detection (SYBR green), and no specialized probes miR-ID helps keep costs low and allows for the rapid development of assays for miRNAs of interest."
In addition to applications with purified RNA samples, miR-ID has been incorporated into SomaGenics' miR-Direct technology for the direct quantification of microRNA from plasma or serum. miR-Direct utilizes solution-phase hybridization to capture probes, greatly improving the detection of low-abundance miRNAs over solid-state capture methods. This step allows concentration of target miRNAs and washing miRNAs to remove qPCR inhibitors, such as heparin, from plasma. By using a capture probe, miR-Direct eliminates the need for total RNA isolation, the most problematic and bias-prone step in currently available miRNA detection kits.
The miR-Direct/ID technology was introduced at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society, which was held October 11-14, 2015, in Leiden, the Netherlands.
Related Links:
SomaGenics
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
The biotechnology company SomaGenics (Santa Cruz, CA, USA) has announced the launch of its novel miR-ID platform and assays for detecting miRNA using a circularization-based RT-qPCR method.
The miR-ID platform is highly sensitive, uses single-dye detection, and can discriminate miRNA isoforms with single nucleotide differences at any position along the molecule. The technology works well with all sample sources, including total RNA, cell lysates, and tissue lysates.
"The miR-ID miRNA detection platform is highly sensitive and provides much better sequence discrimination than leading competitors," said Brian Johnston, CEO of SomaGenics. "By using unmodified DNA primers, single-dye detection (SYBR green), and no specialized probes miR-ID helps keep costs low and allows for the rapid development of assays for miRNAs of interest."
In addition to applications with purified RNA samples, miR-ID has been incorporated into SomaGenics' miR-Direct technology for the direct quantification of microRNA from plasma or serum. miR-Direct utilizes solution-phase hybridization to capture probes, greatly improving the detection of low-abundance miRNAs over solid-state capture methods. This step allows concentration of target miRNAs and washing miRNAs to remove qPCR inhibitors, such as heparin, from plasma. By using a capture probe, miR-Direct eliminates the need for total RNA isolation, the most problematic and bias-prone step in currently available miRNA detection kits.
The miR-Direct/ID technology was introduced at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society, which was held October 11-14, 2015, in Leiden, the Netherlands.
Related Links:
SomaGenics
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Multi-Chamber Washer-Disinfector
WD 390
Electrolyte Analyzer
BKE-B
Latest BioResearch News
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
Channels
Clinical Chemistry
view channel
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read more
Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
Early diagnosis of liver fibrosis remains challenging because the condition often progresses without symptoms, while traditional assessments rely on invasive biopsy or costly imaging. Timely identification... Read more
Molecular Diagnostics
view channel
HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
Cervical cancer is the fourth most common cancer in women and is largely preventable through vaccination and regular screening. However, even where organized screening programs exist, participation varies... Read more
Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Pathology
view channel
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more
